Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors
Conditions
Interventions
EIS-12656
Olaparib
+1 more
Locations
1
United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
September 9, 2024
Primary Completion Date
September 1, 2027
Completion Date
December 1, 2027
Last Updated
September 19, 2024
NCT07177937
NCT07181681
NCT05919264
NCT06257264
NCT07387068
NCT07360314
Lead Sponsor
Eisbach Bio GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions